Optimizing human post-mortem brain tissue gene expression profiling in Parkinson's disease and other neurodegenerative disorders: From target "fishing" to translational breakthroughs

Journal of Neuroscience Research

Volumn 85, Issue 14, 2007, Pages 3013-3024

  Papapetropoulos, Spiridon ^a   Shehadeh, Lina ^a,b   McCorquodale, Donald ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b FLORIDA ATLANTIC UNIVERSITY   (United States)

Author keywords

Gene expression profiling; Microarrays; Parkinson's disease; Post mortem brain

Indexed keywords

ALZHEIMER DISEASE; BRAIN TISSUE; CLINICAL EVALUATION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE TARGETING; HUMAN; MICROARRAY ANALYSIS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REVIEW; TISSUE MICROARRAY; TISSUE PRESERVATION;

GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; MICROARRAY ANALYSIS; NEURODEGENERATIVE DISEASES; POSTMORTEM CHANGES;

EID: 35848933663     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21355     Document Type: Review

References (80)

1. Andersen CL, Jensen JL, Orntoft TF. 2004. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64:5245-5250.
2. Ascherio A, Chen H, Weisskopf MG, O'Reilly E, McCullough ML, Calle EE, Schwarzschild MA, Thun MJ. 2006. Pesticide exposure and risk for Parkinson's disease. Ann Neurol (in press).
3. Bahn S, Augood SJ, Ryan M, Standaert DG, Starkey M, Emson PC. 2001. Gene expression profiling in the post-mortem human brain - no cause for dismay. J Chem Neuroanat 22:79-94.
4. Barton AJ, Pearson RC, Najlerahim A, Harrison PJ. 1993. Pre- and post-mortem influences on brain RNA. J Neurochem 61:1-11.
5. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. 1961. An inventory for measuring depression. Arch Gen Psychiatry 4:561-571.
6. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. 2004. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A 101:2173-2178.
7. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA, Heutink P. 2003. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299:256-259.
8. Cacabelos R, Fernandez-Novoa L, Lombardi V, Kubota Y, Takeda M. 2005. Molecular genetics of Alzheimer's disease and aging. Methods Find Exp Clin Pharmacol 27(Suppl A):1-573.
9. Canales RD, Luo Y, Willey JC, Austermiller B, Barbacioru CC, Boysen C, Hunkapiller K, Jensen RV, Knight CR, Lee KY, Ma Y, Maqsodi B, Papallo A, Peters EH, Poulter K, Ruppel PL, Samaha RR, Shi L, Yang W, Zhang L, Goodsaid FM. 2006. Evaluation of DNA microarray results with quantitative gene expression platforms. Nat Biotechnol 24:1115-1122.
10. Castensson A, Emilsson L, Preece P, Jazin EE. 2000. High-resolution quantification of specific mRNA levels in human brain autopsies and biopsies. Genome Res 10:1219-1229.
11. Corey-Bloom J. 2002. The ABC of Alzheimer's disease: cognitive changes and their management in Alzheimer's disease and related dementias. Int Psychogeriatr 14(Suppl 1):51-75.
12. Dickson DW. 2005. Required techniques and useful molecular markers in the neuropathologic diagnosis of neurodegenerative diseases. Acta Neuropathol 109:14-24.
13. Eisen MB, Spellman PT, Brown PO, Botstein D. 1998. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95:14863-14868.
14. Emborg ME. 2004. Evaluation of animal models of Parkinson's disease for neuroprotective strategies. J Neurosci Methods 139:121-143.
15. Fahn S, Elton RL,Members of the UPDRS Development Committee. 1987. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, editors. Recent developments in Parkinson's disease, 2nd ed. Florham Park, NJ: Macmillan Health Care Information. p 153-164.
16. Farrer MJ. 2006. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 7:306-318.
17. Florell SR, Coffin CM, Holden JA, Zimmermann JW, Gerwels JW, Summers BK, Jones DA, Leachman SA. 2001. Preservation of RNA for functional genomic studies: a multidisciplinary tumor bank protocol. Mod Pathol 14:116-128.
18. Folstein MF, Folstein SE, McHugh PR. 1975. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198.
19. Galvin JE, Ginsberg SD. 2005. Expression profiling in the aging brain: a perspective. Ageing Res Rev (in press).
20. Ginsberg SD, Hemby SE, Lee VM, Eberwine JH, Trojanowski JQ. 2000. Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. Ann Neurol 48:77-87.
21. Ginsberg SD, Elarova I, Ruben M, Tan F, Counts SE, Eberwine JH, Trojanowski JQ, Hemby SE, Mufson EJ, Che S. 2004. Single-cell gene expression analysis: implications for neurodegenerative and neuropsychiatric disorders. Neurochem Res 29:1053-1064.
22. Ginsberg SD, Che S, Counts SE, Mufson EJ. 2006. Single cell gene expression profiling in Alzheimer's disease. NeuroRx 3:302-318.
23. Godfrey TE, Kim SH, Chavira M, Ruff DW, Warren RS, Gray JW, Jensen RH. 2000. Quantitative mRNA expression analysis from formalin-fixed, paraffin-embedded tissues using 5′ nuclease quantitative reverse transcription-polymerase chain reaction. J Mol Diagn 2:84-91.
24. Goldman SM, Tanner CM, Oakes D, Bhudhikanok GS, Gupta A, Langsten JW. 2006. Head injury and Parkinson's disease risk in twins. Ann Neurol 60:65-72.
25. Grandinetti A, Morens DM, Reed D, MacEachern D. 1994. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. Am J Epidemiol 139:1129-1138.
26. Grunblatt E, Mandel S, Jacob-Hirsch J, Zeligson S, Amariglo N, Rechavi G, Li J, Ravid R, Roggendorf W, Riederer P, Youdim MB. 2004. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 111:1543-1573.
27. Hardy JA, Wester P, Winblad B, Gezelius C, Bring G, Eriksson A. 1985. The patients dying after long terminal phase have acidotic brains; implications for biochemical measurements on autopsy tissue. J Neural Transm 61:253-264.
28. Harrison PJ, Barton AJ, Najlerahim A, McDonald B, Pearson RC. 1991. Regional and neuronal reductions of polyadenylated messenger RNA in Alzheimer's disease. Psychol Med 21:855-866.
29. Harrison PJ, Heath PR, Eastwood SL, Burnet PW, McDonald B, Pearson RC. 1995. The relative importance of premortem acidosis and postmortem interval for human brain gene expression studies: selective mRNA vulnerability and comparison with their encoded proteins. Neurosci Lett 200:151-154.
30. Hauser MA, Li YJ, Xu H, Noureddine MA, Shao YS, Gullans SR, Scherzer CR, Jensen RV, McLaurin AC, Gibson JR, Scott BL, Jewett RM, Stenger JE, Schmechel DE, Hulette CM, Vance JM. 2005. Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. Arch Neurol 62:917-921.
31. Hoehn MM, Yahr MD. 1967. Parkinsonism: onset, progression and mortality. Neurology 17:427-442.
32. Hollingshead D, Lewis DA, Mirnics K. 2005. Platform influence on DNA microarray data in postmortem brain research. Neurobiol Dis 18:649-655.
33. Hynd MR, Lewohl JM, Scott HL, Dodd PR. 2003. Biochemical and molecular studies using human autopsy brain tissue. J Neurochem 85:543-562.
34. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. 2003. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31:e15.
35. Jackson DP, Lewis FA, Taylor GR, Boylston AW, Quirke P. 1990. Tissue extraction of DNA and RNA and analysis by the polymerase chain reaction. J Clin Pathol 43:499-504.
36. Johnson SA, Morgan DG, Finch CE. 1986. Extensive postmortem stability of RNA from rat and human brain. J Neurosci Res 16:267-280.
37. Johnston NL, Cervenak J, Shore AD, Torrey EF, Yolken RH. 1997. Multivariate analysis of RNA levels from postmortem human brains as measured by three different methods of RT-PCR.Stanley Neuropathology Consortium. J Neurosci Methods 77:83-92.
38. Katsel PL, Davis KL, Haroutunian V. 2005. Large-scale microarray studies of gene expression in multiple regions of the brain in schizophrenia and Alzheimer's disease. Int Rev Neurobiol 63:41-82.
39. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. 1998. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605-608.
40. Klebanov L, Yakovlev A. 2006. Treating expression levels of different genes as a sample in microarray data analysis: is it worth a risk? Stat Appl Genet Mol Biol, vol 5, article 9.
41. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein MJ, Jonnalagada S, Chernova T, Dehejia A, Lavedan C, Gasser T, Steinbach PJ, Wilkinson KD, Polymeropoulos MH. 1998. The ubiquitin pathway in Parkinson's disease. Nature 395:451-452.
42. Li JZ, Vawter MP, Walsh DM, Tomita H, Evans SJ, Choudary PV, Lopez JF, Avelar A, Shokoohi V, Chung T, Mesarwi O, Jones EG, Watson SJ, Akil H, Bunney WE Jr, Myers RM. 2004. Systematic changes in gene expression in postmortem human brains associated with tissue pH and terminal medical conditions. Hum Mol Genet 13:609-616.
43. Li MD, Konu O, Kane JK, Becker KG. 2002. Microarray technology and its application on nicotine research. Mol Neurobiol 25:265-285.
44. Loring JF, Wen X, Lee JM, Seilhamer J, Somogyi R. 2001. A gene expression profile of Alzheimer's disease. DNA Cell Biol 20:683-695.
45. Mandel S, Grunblatt E, Riederer P, Amariglio N, Jacob-Hirsch J, Rechavi G, Youdim MB. 2005. Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann N Y Acad Sci 1053:356-375.
46. Mariani TJ, Budhraja V, Mecham BH, Gu CC, Watson MA, Sadovsky Y. 2003. A variable fold change threshold determines significance for expression microarrays. FASEB J 17:321-323.
47. Miller CL, Diglisic S, Leister F, Webster M, Yolken RH. 2004. Evaluating RNA status for RT-PCR in extracts of postmortem human brain tissue. Biotechniques 36:628-633.
48. Miller RM, Kiser GL, Kaysser-Kranich TM, Lockner RJ, Palaniappan C, Federoff HJ. 2006. Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson's disease. Neurobiol Dis 21:305-313.
49. Mimmack ML, Brooking J, Bahn S. 2004. Quantitative polymerase chain reaction: validation of microarray results from postmortem brain studies. Biol Psychiatry 55:337-345.
50. Mirnics K, Pevsner J. 2004. Progress in the use of microarray technology to study the neurobiology of disease. Nat Neurosci 7:434-439.
51. Model F, Konig T, Piepenbrock C, Adorjan P. 2002. Statistical process control for large scale microarray experiments. Bioinformatics 18(Suppl 1):S155-S163.
52. Moran LB, Duke DC, Deprez M, Dexter DT, Pearce RK, Graeber MB. 2006. Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease. Neurogenetics 7:1-11.
53. Mufson EJ, Counts SE, Ginsberg SD. 2002. Gene expression profiles of cholinergic nucleus basalis neurons in Alzheimer's disease. Neurochem Res 27:1035-1048.
54. Ogden CA, Rich ME, Schork NJ, Paulus MP, Geyer MA, Lohr JB, Kuczenski R, Niculescu AB. 2004. Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: an expanded convergent functional genomics approach. Mol Psychiatry 9:1007-1029.
55. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, Singleton AB. 2004. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44:595-600.
56. Papapetropoulos S, ffrench-Mullen J, McCorquodale D, Qin Y, Pablo J, Mash DC. 2006a. Multiregional gene expression profiling identifies MRPS6 as a candidate gene for Parkinson's disease. Gene Express 13:205-215.
57. Papapetropoulos S, McCorquodale DS, Gonzalez J, Jean-Gilles L, Mash DC. 2006b. Cortical and amygdalar Lewy body burden in Parkinson's disease patients with visual hallucinations. Parkinsonism Rel Disord 12:253-256.
58. Papapetropoulos S, Villar JM, Gonzalez J, Mash DC. 2006c. Disparities in death certificates of Parkinson's disease patients: a report from a population of brain donors. Mov Disord 21:1791-1792.
59. Papapetropoulos S, McCorquodale D. 2007. Gene expression profiling in Parkinson's disease: discovery of valid biomarkers, molecular targets and biochemical pathways. Future Neurol 2:29-38.
60. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047.
61. Qiu X, Klebanov L, Yakovlev A. 2005. Correlation between gene expression levels and limitations of the empirical bayes methodology for finding differentially expressed genes. Stat Appl Genet Mol Biol 4:Article34.
62. Ravid R, Van Zwieten EJ, Swaab DF. 1992. Brain banking and the human hypothalamus - factors to match for, pitfalls and potentials. Prog Brain Res 93:83-95.
63. Roberge RJ, Krenzelok EP. 2001. Prolonged coma and loss of brainstem reflexes following amitriptyline overdose. Vet Hum Toxicol 43:42-44.
64. Ryan MM, Huffaker SJ, Webster MJ, Wayland M, Freeman T, Bahn S. 2004. Application and optimization of microarray technologies for human postmortem brain studies. Biol Psychiatry 55:329-336.
65. Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, Schwarzschild MA, Schlossmacher MG, Hauser MA, Vance JM, Sudarsky LR, Standaert DG, Growdon JH, Jensen RV, Gullans SR. 2007. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A 104:955-960.
66. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M, Lightfoot S, Menzel W, Granzow M, Ragg T. 2006. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 7:3.
67. Sequeira A, Gwadry FG, Ffrench-Mullen JM, Canetti L, Gingras Y, Casero RA, Jr., Rouleau G, Benkelfat C, Turecki G. 2006. Implication of SSAT by gene expression and genetic variation in suicide and major depression. Arch Gen Psychiatry 63:35-48.
68. Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ, de Longueville F, Kawasaki ES, Lee KY, Luo Y, Sun YA, Willey JC, Setterquist RA, Fischer GM, Tong W, Dragan YP, Dix DJ, Frueh FW, Goodsaid FM, Herman D, Jensen RV, Johnson CD, Lobenhofer EK, Puri RK, Scherf U, Thierry-Mieg J, Wang C, Wilson M, Wolber PK, Zhang L, Amur S, Bao W, Barbacioru CC, Lucas AB, Bertholet V, Boysen C, Bromley B, Brown D, Brunner A, Canales R, Cao XM, Cebula TA, Chen JJ, Cheng J, Chu TM, Chudin E, Corson J, Corton JC, Croner LJ, Davies C, Davison TS, Delenstarr G, Deng X, Dorris D, Eklund AC, Fan XH, Fang H, Fulmer-Smentek S, Fuscoe JC, Gallagher K, Ge W, Guo L, Guo X, Hager J, Haje PK, Han J, Han T, Harbottle HC, Harris SC, Hatchwell E, Hauser CA, Hester S, Hong H, Hurban P, Jackson SA, Ji H, Knight CR, Kuo WP, Leclerc JE, Levy S, Li QZ, Liu C, Liu Y, Lombardi MJ, Ma Y, Magnuson SR, Maqsodi B, McDaniel T, Mei N, Myklebost O, Ning B, Novoradovskaya N, Orr MS, Osborn TW, Papallo A, Patterson TA, Perkins RG, Peters EH, Peterson R, Philips KL, Pine PS, Pusztai L, Qian F, Ren H, Rosen M, Rosenzweig BA, Samaha RR, Schena M, Schroth GP, Shchegrova S, Smith DD, Staedder F, Su Z, Sun H, Szallasi Z, Tezak Z, Thierry-Mieg D, Thompson KL, Tikhonova I, Turpaz Y, Vallanat B, Van C, Walker SJ, Wang SJ, Wang Y, Wolfinger R, Wong A, Wu J, Xiao C, Xie Q, Xu J, Yang W, Zhang L, Zhong S, Zong Y, Slikker W Jr. 2006. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 24:1151-1161.
69. Shulzhenko N, Yambartsev A, Goncalves-Primo A, Gerbase-DeLima M, Morgun A. 2005. Selection of control genes for quantitative RT-PCR based on microarray data. Biochem Biophys Res Commun 337:306-312.
70. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. 2003. Alpha-synuclein locus triplication causes Parkinson's disease. Science 302:841.
71. Tanner CM. 2003. Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies. Adv Neurol 91:133-142.
72. Tomita H, Vawter MP, Walsh DM, Evans SJ, Choudary PV, Li J, Overman KM, Atz ME, Myers RM, Jones EG, Watson SJ, Akil H, Bunney WE Jr. 2004. Effect of agonal and postmortem factors on gene expression profile: quality control in microarray analyses of postmortem human brain. Biol Psychiatry 55:346-352.
73. Trotter SA, Brill LB 2nd, Bennett JP Jr. 2002. Stability of gene expression in postmortem brain revealed by cDNA gene array analysis. Brain Res 942:120-123.
74. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, Gonzalez-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW. 2004. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304:1158-1160.
75. Wu Z, Irizarry RA, Gentleman RC, Martinez-Murillo F, Spencer F. 2004. A model based background adjustment for oligonucleotide expression arrays. J Am Stat Assoc 99:909-917.
76. Yao PJ, Zhu M, Pyun EI, Brooks AI, Therianos S, Meyers VE, Coleman PD. 2003. Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer's disease. Neurobiol Dis 12:97-109.
77. Yasojima K, McGeer EG, McGeer PL. 2001. High stability of mRNAs postmortem and protocols for their assessment by RT-PCR. Brain Res Brain Res Protoc 8:212-218.
78. Yokota H, Yamamoto Y, Naoe Y, Fuse A, Sato H, Unemoto K, Kurokawa A. 2000. Measurements of cortical cellular pH by intracranial tonometer in severe head injury. Crit Care Med 28:3275-3280.
79. Zhang Y, James M, Middleton FA, Davis RL. 2005. Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms. Am J Med Genet B Neuropsychiatr Genet 137:5-16.
80. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T. 2004. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601-607.